InterMune Price Target Raised to $74.00 at Leerink Swann (ITMN)
Equities research analysts at Leerink Swann upped their price objective on shares of InterMune (NASDAQ:ITMN) from $53.00 to $74.00 in a research note issued to investors on Monday. Leerink Swann’s price target suggests a potential upside of 37.55% from the stock’s previous close.
InterMune (NASDAQ:ITMN) opened at 53.80 on Monday. InterMune has a 52 week low of $10.95 and a 52 week high of $55.24. The stock’s 50-day moving average is $45.86 and its 200-day moving average is $36.13. The company’s market cap is $5.809 billion.
InterMune (NASDAQ:ITMN) last announced its earnings results on Wednesday, August 6th. The company reported ($0.72) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter in the prior year, the company posted ($0.77) earnings per share. The company’s quarterly revenue was up 141.2% on a year-over-year basis. On average, analysts predict that InterMune will post $-2.75 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on ITMN. Analysts at Robert W. Baird raised their price target on shares of InterMune from $50.00 to $74.00 in a research note on Monday. Separately, analysts at Wells Fargo & Co. downgraded shares of InterMune from an “outperform” rating to a “market perform” rating in a research note on Thursday. They noted that the move was a valuation call. Finally, analysts at Goldman Sachs downgraded shares of InterMune from a “buy” rating to a “neutral” rating in a research note on Thursday, August 14th. They now have a $49.00 price target on the stock, down previously from $52.06. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $50.08.
In other InterMune news, EVP Paul D. Arata sold 7,500 shares of InterMune stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $50.00, for a total transaction of $375,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.